Project supported by National Science Council grants (NSC 93-2311-B-010-001 and NSC 93-3112-B-010-010)
Telomere and telomerase as targets for anti-cancer and regeneration therapies1
Article first published online: 10 MAY 2005
Acta Pharmacologica Sinica
Volume 26, Issue 5, pages 513–518, May 2005
How to Cite
HSU, Y.-h. and LIN, J.-j. (2005), Telomere and telomerase as targets for anti-cancer and regeneration therapies. Acta Pharmacologica Sinica, 26: 513–518. doi: 10.1111/j.1745-7254.2005.00098.x
We thank Yu-ling LEE for reading the manuscript.
- Issue published online: 10 MAY 2005
- Article first published online: 10 MAY 2005
- Received 2004-12-30; Accepted 2005-01-18
- regenerative disease;
- gene therapy
Telomerase is a ribonucleoprotein that directs the synthesis of telomeric sequence. It is detected in majority of malignant tumors, but not in most normal somatic cells. Because telomerase plays a critical role in cell immortality and tumor formation, it has been one of the targets for anti-cancer and regeneration drug development. In this review, we will discuss therapeutic approaches based mainly on small molecules that have been developed to inhibit telomerase activity, modulate telomerase expression, and telomerase directed gene therapy.